SEATTLE--(BUSINESS WIRE)--Blaze Bioscience, Inc., the Tumor Paint Company®, a biotechnology company focused on guided cancer therapy, announced today that the company’s Senior Vice President of Development, Dennis Miller, Ph.D., will present at the American Society of Surgical Oncology (ASCO) 2016 Annual Meeting, taking place in Chicago, IL on June 3-7, 2016.
The poster presentation, titled “Phase 1 Dose Escalation and Expansion Safety Study of BLZ-100 in Pediatric Subjects with Primary Central Nervous System Tumors,” will highlight the company’s first study in the pediatric population.
BLZ-100 is the first product candidate from Blaze’s Tumor Paint platform and consists of an Optide (optimized peptide) and a fluorescent dye, which emits light in the near-infrared range. Tumor Paint products are designed to provide real-time, high-resolution intraoperative visualization of cancer cells, potentially enabling more precise, complete resection of cancer throughout surgery. Preclinical utility of Tumor Paint technology has been demonstrated in a wide range of cancer types. BLZ-100 is an investigational agent currently in multiple Phase 1 proof-of-concept clinical studies to evaluate the safety and imaging characteristics of BLZ-100 in solid tumors, including brain, breast, lung, prostate, and colorectal cancer. More details about on-going trials are available at www.blazebioscience.com or www.clinicaltrials.gov.
Read more: http://www.businesswire.com/news/home/20160531005190/en/Blaze-Bioscience-Announces-Trial-Progress-Presentation-ASCO